computational binding models, and GPU compute to engineer novel peptide structures that bind clinical targets. This AI-driven process enables design-build-test cycles in roughly four weeks, with validated hit rates that exceed conventional benchmarks; the platform also supports multi-objective optimization, balancing traits like specificity, half-life, and solubility simultaneously. Aizen advances its pipeline through stages such as discovery, IND-enabling studies, and Phase 1 trials across areas including neurological disorders, oncology, and genetic diseases.